Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
JNJ-89853413 in Acute Myeloid Leukemia: NCT06618001 Clinical Landscape Report 2026
16 October 2026
NCT06618001 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT06621199 Clinical Landscape Report 2026
16 October 2026
NCT06621199 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pyridoxine Hydrochloride in Tuberculosis: NCT06618573 Clinical Landscape Report 2026
16 October 2026
NCT06618573 clinical landscape for Tuberculosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ciltacabtagene autoleucel in Multiple Myeloma: NCT06623630 Clinical Landscape Report 2026
16 October 2026
NCT06623630 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cisplatin in Muscle Invasive Bladder Carcinoma: NCT06623162 Clinical Landscape Report 2026
16 October 2026
NCT06623162 clinical landscape for Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
DB-2304 in Lupus Erythematosus, Cutaneous: NCT06625671 Clinical Landscape Report 2026
16 October 2026
NCT06625671 clinical landscape for Lupus Erythematosus, Cutaneous: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carfilzomib in Recurrent Multiple Myeloma: NCT06627751 Clinical Landscape Report 2026
16 October 2026
NCT06627751 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CRD-3874 in Refractory acute myeloid leukemia: NCT06626633 Clinical Landscape Report 2026
16 October 2026
NCT06626633 clinical landscape for Refractory acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Disitamab Vedotin in HER2-Expressing Non-Muscle Invasive Bladder Neoplasms: NCT06630871 Clinical Landscape Report 2026
16 October 2026
NCT06630871 clinical landscape for HER2-Expressing Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and d…
9 min read
SAR-446523 in Multiple Myeloma: NCT06630806 Clinical Landscape Report 2026
16 October 2026
NCT06630806 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pemetrexed Dipotassium in Metastatic Solid Tumor: NCT06630416 Clinical Landscape Report 2026
16 October 2026
NCT06630416 clinical landscape for Metastatic Solid Tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Donor NK Cell(Peking University First Hospital) in Acute Myeloid Leukemia: NCT06641648 Clinical Landscape Report 2026
16 October 2026
NCT06641648 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.